BCM
DRNA

BlueCrest Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

BlueCrest Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,500
Closed -$252K – 1590
2018
Q3 		$252K Buy
+16,500
New +$240K 0.01% 1135
2018
Q2 		– Sell
-114,650
Closed -$1.1M – 1962
2018
Q1 		$1.1M Buy
+114,650
New +$1.24M 0.03% 460

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's DRNA Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2018, closing a stake of 16,500 shares — an estimated $252K sold.

BlueCrest Capital Management first reported a position in DRNA in Q1 2018 and held it in 2 quarters. The position peaked at $1.1M in Q1 2018. 103 funds tracked by Wall St. Rank hold DRNA as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 16,500 Dicerna Pharmaceuticals, Inc. shares in Q4 2018, an estimated $252K.
  • BlueCrest Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $1.1M in Q1 2018.
  • 103 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.